741MO Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), demonstrates clinical activity in recurrent/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase I dose expansion

B. Pothuri,R.W. Naumann,L.P. Martin, D. O'Malley, D. Uyar, J.W. Moroney,J. Diaz, J. Garcia-Donas,A. Redondo Sanchez,A. Gonzalez Martin, D.G. Illescas, L. Liu, C. Berman, A. Oaknin

Annals of Oncology（2023）

引用 0|浏览3

暂无评分

关键词

recurrent/progressive epithelial endometrial cancer,endometrial cancer,antibody drug conjugate,anti-folate

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要